CER Daily Newsfeed

Value Viewpoint: July 25, 2025

(7/25, Kimberly Westrich, LinkedIn) comments “A new article published in the Journal of Comparative Effectiveness Research examines how to broaden the scope of value assessments to encompass healthcare services and procedures, considering the current political context. The authors point out: ‘As we and other researchers have noted, the problem of low value care is particularly acute for health services and procedures, which comprise roughly 70% of healthcare spending but have received relatively limited attention in value assessments. Moreover, unlike prescription drugs, which eventually go generic or attract biosimilar competition thus driving down prices, health services and procedures usually experience price increases over time.’” Full

Study Explores the Survival Advantage of GLP-1s in Cancer Patients With Diabetes

(7/27, Kennedy Ferruggia, Pharmacy Times) reports “...A study found GLP-1 use linked to lower all-cause mortality compared to DPP4 inhibitors, with no significant difference from SGLT2 inhibitors.” Full

GLP-1RAs Linked With Improved Survival in Patients With Cancer and T2DM

(7/28, Kyle Grgecic, Renal & Urology News) reports “...‘While causality cannot be inferred, our study adds novel evidence on the comparative effectiveness of GLP-1RAs,’ Dr Guo’s team wrote. ‘Clinical trials are needed to confirm the role of GLP-1RAs in cancer survivorship.’” Full

Building the Blueprint for Patient-Centered Value Research: An interview with Rick Chapman and Ushma Patel, Center for Innovation & Value Research

(7/28, The Evidence Base) reports “...[Center for Innovation & Value Research’s Rick Chapman and Ushma Patel:] We hope that the Blueprint can serve as a one-stop resource for conducting patient-centered value research, and as a reminder to seek meaningful partnership with patients throughout the research process. The Blueprint can be helpful not only to researchers as they design and conduct studies, but also to patients and patient advocates as they gauge the extent and quality of patient engagement in research projects or technology assessments.” Full

The Art of the Second Act: A Six-Step Framework for Mastering Late-Stage Drug Lifecycle Management

(7/27, Drug Patent Watch) comments “...While [value-based contracts] are complex to design and implement—requiring robust data collection infrastructure and careful navigation of regulatory hurdles like the U.S. Medicaid Best Price rule—they represent the future of pharmaceutical reimbursement.72 They allow manufacturers to stand behind their product’s claims and share the risk with payers, building trust and defending market share based on performance.” Full

US Health, Tech Officials to Launch Data-Sharing Plan

(7/26, Rachel Cohrs Zhang, John Tozzi, Bloomberg) reports “...‘This initiative aims to build a smarter, more secure, and more personalized health care system — one that improves patient outcomes, reduces provider burden, and drives greater value through private-sector innovation and aligned federal leadership,’ CMS spokesperson Catherine Howden said...Companies will commit to a voluntary framework around what’s known as interoperability, or how different health technology systems connect to one another and share data...Improving the flow of data across the fragmented US health-care system has long been a policy goal of both Democratic and Republican administrations seeking to improve quality and reduce waste.” Subscription Required

Video: How Can Real World Data and AI Help Solve Issues with Clinical Trials?

(7/28, Mike Hollan, PharmExec) “Gen Li, president and founder of Phesi, spoke with Pharmaceutical Executive about issues pharma companies are having during Phase III trials and how new technologies can solve these issues.” View Video

Greg Initiative to Boost Real-World Evidence in Europe

(7/28, The Pharma Letter) reports “A new European project, called Greg, has been launched to tackle long-standing challenges around the use of real-world data and evidence in medicines, medical devices, and drug-device combinations...The five-year initiative has a budget of 26 million euros ($27 million) and brings together 29 partners from 15 countries. The consortium includes academics, regulators, health technology assessment (HTA) agencies, and major industry players.” Subscription Required